1. Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test Through 96 Weeks in Phase llb in Duchenne Muscular Dystrophy

    Posted on September 26, 20134:01 pm

    We are encouraged by the promising Phase IIb data for eteplirsen, an exon-skipping compound, which we hope could be a breakthrough treatment for Duchenne muscular dystrophy. Currently, there is no treatment for this most common and lethal form of muscular dystrophy. While eteplirsen would likely work in only 15 percent of those with a specific Read more »

  2. GSK and Prosensa announce primary endpoint not met in Phase III study of drisapersen in patients with Duchenne Muscular Dystrophy

    Posted on September 20, 20131:16 pm

    GlaxoSmithKline (GSK) and Prosensa today announced that GSK’s Phase III clinical study of drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy (DMD) patients with an amenable mutation, did not meet the primary endpoint of a statistically significant improvement in the 6 Minute Walking Distance (6MWD) test compared to placebo. A total Read more »


    Posted on September 11, 201312:18 am

    CureDuchenne has worked closely with biotech and pharmaceutical companies for the past decade with a goal of accelerating treatments for Duchenne muscular dystrophy.  CureDuchenne was the first organization to partner with a biotech company to develop exon skipping to treat Duchenne almost ten years ago when we invested in Prosensa, a Dutch biotech company.  Since Read more »

  4. Thank you Fergie for helping Cure Duchenne!

    Posted on September 5, 201310:50 pm

    Yesterday, Fergie – a Grammy award-winning singer/songwriter, and new mom! -  joined the ranks of talented and respected celebrities we love.  Over the last few years, Clay Matthews, Ryan Getzlaf, Mack Brown and Scott Niedermayer have spoken out publicly in support of CureDuchenne.  We are very touched by Fergie’s support. Fergie is appearing in a Read more »